High-Purity Preparation of HSV-2 Vaccine Candidate ACAM529 Is Immunogenic and Efficacious In Vivo

• Sophia T. Mundle ,

  * E-mail: sophia.mundle@sanofipasteur.com

  Affiliation Discovery North America, Sanofi Pasteur, Cambridge, Massachusetts, United States of America

  ⨯
• Hector Hernandez,

  Affiliation Discovery North America, Sanofi Pasteur, Cambridge, Massachusetts, United States of America

  ⨯
• John Hamberger,

  Affiliation Discovery North America, Sanofi Pasteur, Cambridge, Massachusetts, United States of America

  ⨯
• John Catalan,

  Affiliation Discovery North America, Sanofi Pasteur, Cambridge, Massachusetts, United States of America

  ⨯
• Changhong Zhou,

  Affiliation Discovery North America, Sanofi Pasteur, Cambridge, Massachusetts, United States of America

  ⨯
• Svetlana Stegalkina,

  Affiliation Discovery North America, Sanofi Pasteur, Cambridge, Massachusetts, United States of America

  ⨯
• Andrea Tiffany,

  Affiliation Discovery North America, Sanofi Pasteur, Cambridge, Massachusetts, United States of America

  ⨯
• Harry Kleanthous,

  Affiliation Discovery North America, Sanofi Pasteur, Cambridge, Massachusetts, United States of America

  ⨯
• Simon Delagrave,

  Affiliation Discovery North America, Sanofi Pasteur, Cambridge, Massachusetts, United States of America

  ⨯
• Stephen F. Anderson

  Affiliation Discovery North America, Sanofi Pasteur, Cambridge, Massachusetts, United States of America

  ⨯